The list of benefits for Novo Nordisk's semaglutide keeps getting longer ... City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), compared to an 8.7 reduction with placebo.

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational ...